Profusa, Inc. 2025 Annual Report: Key Highlights and Insights for Investors

Company Overview and Key Developments

Profusa, Inc. (Nasdaq: PFSA), a Delaware corporation headquartered in New York, completed its business combination with Northview Acquisition Corp on July 11, 2025, officially changing its name to Profusa, Inc. The company is now publicly traded on the Nasdaq under the ticker symbol PFSA.

On February 9, 2026, Profusa executed a significant reverse stock split at a ratio of 1-for-75, adjusting all historical share and per-share data on a retrospective basis. Notably, the number of authorized shares and par value remained unchanged, which is important for shareholders to understand as it impacts the share structure but not the underlying value allocation.

Shareholder Information and Market Data

• Shares Outstanding: As of April 14, 2026, Profusa has 4,410,268 shares of common stock outstanding, each with a par value of \$0.0001.
• Market Capitalization: The aggregate market value of voting and non-voting common stock held by non-affiliates was approximately \$1.3 million as of June 30, 2025.
• Listing: Common stock is registered and traded on the Nasdaq Stock Market under the symbol PFSA.

Regulatory and Filing Status

• Profusa is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. This status allows for certain reduced disclosure requirements and extended transition periods for new accounting standards.
• The company is not a shell company and remains current with all SEC reporting obligations.
• No restatements or corrections to previously issued financial statements were indicated, reducing uncertainty for investors.

Business Model and Strategic Vision

Profusa is a medical technology company specializing in minimally invasive biosensors that integrate with body tissue to provide continuous, real-time data on important physiological metrics. The company’s core products include the Lumee Oxygen and Lumee Glucose platforms.

• Innovation Pipeline: The company is actively developing sensors for additional analytes such as lactate, CO₂, ethanol, and pH, aiming to expand its addressable market to other chronic conditions.
• Data Monetization Opportunity: Profusa sees significant potential in monetizing the data streams generated by its biosensors. The expanding telemedicine and health & wellness coaching sectors, which are projected to reach nearly \$400 billion by 2028, represent a substantial growth opportunity if Profusa’s data can become an essential enabler for these platforms.
• Commercial Strategy: The company intends to leverage its scientific leadership, invest in relationships with key opinion leaders (KOLs), and build a network of regional commercial partners. Profusa has already been featured in over 25 peer-reviewed publications, bolstering its clinical credibility.

Intellectual Property Portfolio

Profusa maintains a robust patent portfolio, securing its technology and future revenue streams. Key patents cover “Tissue-Integrating Sensors,” “Oxygen Sensors,” “Near-IR Glucose Sensors,” and more, with expiration dates extending as far as 2039 and coverage in major jurisdictions such as the USA, Europe, China, Japan, South Korea, India, and Israel.

• Patent Expirations: Major patents in the United States and internationally have expiration dates ranging from 2030 to 2039, providing long-term competitive protection.
• Geographic Coverage: The company has successfully secured IP protection in key markets, supporting global commercialization efforts and reducing the risk of competitive encroachment.

Potential Price-Sensitive Issues for Shareholders

• Reverse Stock Split: Investors should note the recent 1-for-75 reverse split, as such corporate actions can impact liquidity, share price, and investor perception.
• Market Capitalization and Float: With a public float of only \$1.3 million, the stock may be subject to high volatility and liquidity risk, which could lead to significant share price movement on relatively low trading volume.
• Emerging Growth Status: As an emerging growth company and smaller reporting company, Profusa has more flexible financial reporting but may face scrutiny as it matures and transitions to full regulatory compliance.
• Commercialization and Data Monetization: Success in monetizing biosensor data and penetrating the telemedicine/wellness market could be highly price sensitive. Investors should monitor partnership announcements, regulatory approvals, and commercial traction.
• Intellectual Property Risks: The value of Profusa’s IP portfolio is significant for its future revenue potential. Any legal challenges or failure to defend these patents could impact long-term value.

Summary for Investors

Profusa, Inc. is at a pivotal stage, having completed a business combination, reverse stock split, and is now focusing on scaling its innovative biosensor platform. The company’s strong patent portfolio, commercial strategy targeting high-growth sectors, and potential for data monetization represent significant upside. However, the small public float and emerging company status mean that the stock could remain volatile and news-sensitive.

Shareholders should remain attuned to regulatory filings, commercialization updates, and partnership announcements, as these could materially move the share price in the near to medium term.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice, an offer, or the solicitation of an offer to buy or sell any securities. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. The author and publisher are not responsible for any losses incurred based on the information provided.

View Profusa, Inc. Historical chart here